Angiogenesis
Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.
-
WP1130 (Degrasyn)
Catalog No. A10988 DUB/Bcr/ABL 抑制剂WP1130 (Degrasyn)是一种新型的选择性小分子去泛素酶抑制剂和Bcr/Abl破坏途径激活剂,可特异性和快速下调野生型和突变型Bcr/Abl蛋白,而不会影响慢性粒细胞性白血病(CML)中的bcr/abl基因表达细胞。 了解更多 -
GNF 2
Catalog No. A11439 -
PD173955
Catalog No. A13120 Bcr-Abl 抑制剂PD-173955是src酪氨酸激酶抑制剂。PD173955抑制Bcr-Abl依赖的细胞生长。PD173955显示G(1)中的细胞周期停滞。PD173955在Bcr-Abl的激酶抑制测定中的IC(50)为1-2 nM,在细胞生长测定中,其抑制Bcr-Abl依赖性底物酪氨酸磷酸化。 PD173955抑制试剂盒配体依赖性c-kit自磷酸化(IC(50)=约25 nM)和试剂盒配体依赖性M07e细胞增殖(IC(50)= 40 nM),但对白介素3依赖性(IC (50)= 250 nM)或粒细胞巨噬细胞集落刺激因子(IC(50)= 1 microM)依赖性细胞生长。 了解更多 -
NRC-AN-019
Catalog No. A13562 Bcr-Abl 抑制剂NRC-AN-019是Bcr-Abl蛋白-酪氨酸激酶的口服酪氨酸激酶抑制剂(TKI)。NRC-AN-019在抑制MDAMB231和HTB20/BT474细胞的血管生成潜力和增殖方面更有效。 了解更多 -
Nilotinib monohydrochloride monohydrate
Catalog No. A15186 -
Radotinib (IY-5511)
Catalog No. A13029 -
GZD824
Catalog No. A16264 -
GZD824 Dimesylate
Catalog No. A15849 Bcr-Abl 抑制剂GZD824 Dimesylate是Bcr-Abl(WT)和Bcr-Abl(T315I)的新型生物可用Bcr-Abl抑制剂,IC50分别为0.34 nM和0.68 nM。 了解更多 -
Lyn-IN-1
Catalog No. A16265 -
SNIPER(ABL)-062
Catalog No. A18567 ABL inhibitorSNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the BCR-ABL protein. 了解更多 -
CHMFL-ABL-121
Catalog No. A19079 ABL2 inhibitorCHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively. 了解更多 -
CHMFL-ABL-039
Catalog No. A13182 BCR-ABL inhibitorCHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia. 了解更多 -
BCR-ABL-IN-1
Catalog No. A12496 BCR-ABL inhibitorBCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. 了解更多 -
CHMFL-ABL/KIT-155
Catalog No. A12421 ABL/c-KIT dual kinase inhibitorCHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. 了解更多 -
1-Naphthyl PP1 hydrochloride
Catalog No. A21790 Src/c-Abl inhibitor1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). 了解更多 -
BCR-ABL-IN-2
Catalog No. A21043 inhibitor of BCR-ABL1 tyrosine kinaseBCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. 了解更多 -
NVP-BHG712
Catalog No. A10661 EphB4 抑制剂NVP-BHG712是EphB4激酶的选择性抑制剂,在体外对EphB4的选择性超过40多种其他激酶(包括FGFR3)。 了解更多 -
DCC-2036 (Rebastinib)
Catalog No. A11200 Bcr-Abl 抑制剂DCC-2036 (Rebastinib)是一种Bcr-Abl抑制剂,作用于Abl1(WT)和Abl1(T315I),IC50分别为0.8 nM和4 nM,也抑制SRC, LYN, FGR, HCK, KDR, FLT3,和Tie-2,对c-Kit具有低的抑制活性。 了解更多 -
Nilotinib (AMN-107)
Catalog No. A10644 Bcr-Abl 抑制剂Nilotinib (AMN-107)是一种Bcr-Abl抑制剂,IC50小于30 nM。 了解更多 -
Saracatinib (AZD0530)
Catalog No. A10108 Src/Abl 抑制剂Saracatinib (AZD0530)是一种高选择性,双特异性Src/Abl激酶抑制剂,对c-Src和Abl激酶的IC50分别为2.7和30 nM。 了解更多 -
Bafetinib (INNO-406)
Catalog No. A10119 Bcr-Abl 抑制剂Bafetinib (INNO-406)是一种双重Bcr-Abl/Lyn酪氨酸激酶抑制剂。 了解更多 -
Dasatinib (BMS-354825)
Catalog No. A10290 Abl-Src 抑制剂Dasatinib (BMS-354825)是一种口服多BCR/ABL和Src家族酪氨酸激酶抑制剂。Dasatinib (BMS-354825)的主要靶标是BCR/ABL,Src,c-Kit,ephrin受体和其他几种酪氨酸激酶,但不是erbB激酶,例如EGFR或Her2。 了解更多 -
R935788 (Fostamatinib disodium, R788)
Catalog No. A10771 Syk 抑制剂R935788 (Fostamatinib disodium,R788)是一种有效的口服Syk抑制剂,可通过阻断抗原依赖性B细胞受体信号传导来抑制CLL的Eμ-TCL1转基因小鼠模型中的肿瘤生长。 了解更多 -
Piceatannol
Catalog No. A12162 -
GS-9973 (Entospletinib)
Catalog No. A13884 -
PRT062607 HCL
Catalog No. A12731 Syk 抑制剂PRT2607,也称为PRT062607,P505-15和BIIB057,是一种新型,高度选择性且口服可生物利用的小分子SYK抑制剂(SYK IC(50)= 1 nM),具有至少80倍的抗SYK活性 大于对其他激酶的亲和力。 了解更多 -
Gusacitinib
Catalog No. A19883 SYK/JAK inhibitorGusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. 了解更多 -
PRT 062070 (Cerdulatinib)
Catalog No. A14147 Dual Syk and JAK 抑制剂PRT 062070 (Cerdulatinib)是一种新型的口服双脾酪氨酸激酶(Syk)和janus激酶(JAK)抑制剂。Cerdulatinib优先抑制各种细胞类型中JAK1和JAK3依赖性细胞因子介导的信号传导和功能性反应。 了解更多 -
BAY 61-3606 dihydrochloride
Catalog No. A15017 -
R112
Catalog No. A14161 -
Lanraplenib
Catalog No. A12959 SYK inhibitorLanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. 了解更多 -
Fostamatinib disodium hexahydrate
Catalog No. A21873 Syk inhibitorFostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM. 了解更多 -
TAK-659 hydrochloride
Catalog No. A21885 Syk inhibitorTAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. 了解更多 -
P505-15 (PRT062607, BIIB057)
Catalog No. A11952 Syk 抑制剂P505-15 (PRT062607,BIIB057)是一种新型的,高度选择性的,Syk抑制剂(SYK IC(50)= 1 nM),具有比SYK活性至少高80倍的抗SYK活性。 了解更多 -
BAY 61-3606
Catalog No. A11320 Syk 抑制剂BAY 61-3606是一种细胞可渗透的咪唑并嘧啶化合物,可作为Syk酪氨酸激酶活性的有效,ATP竞争性,可逆和高度选择性抑制剂,而对Btk,Fyn,Itk,Lyn和Src无抑制作用。 了解更多 -
R788 (Fostamatinib)
Catalog No. A11926 Syk 抑制剂R788 (Fostamatinib)是重要的脾酪氨酸激酶(Syk)抑制剂,显示出对激酶介导的IgG Fcγ受体信号转导的功效。 了解更多 -
PF-03814735
Catalog No. A11171 Aurora A/B Kinase 抑制剂PF-03814735是一种新颖,有效且可逆的Aurora A/B抑制剂,IC50为0.8 nM/5 nM,对Flt3,FAK,TrkA的效力较低,对Met和FGFR1的活性最低。 了解更多 -
PF-00562271
Catalog No. A12580 FAK 抑制剂PF-00562271是PF-562271的苯磺酸盐,是一种有效的,ATP竞争性,可逆的FAK和Pyk2抑制剂,IC50分别为1.5 nM和14 nM。 了解更多 -
PF-4618433
Catalog No. A13461 -
NVP-TAE 226
Catalog No. A11507 FAK 抑制剂NVP-TAE 226是一种强效FAK抑制剂,IC50为5.5 nM,对pyk2(IC50=3.5 nM)有适度的强效作用;对InsR, IGF-1R, ALK和c-Met的效力降低10-100倍。 了解更多